Recall of one batch of RAN-Gabapentin 100 mg capsules due to cross-contamination with Etodolac

Ranbaxy Pharmaceuticals Canada Inc., in consultation with Health Canada, is recalling one batch of RAN-Gabapentin, a medication used to treat epilepsy, due to cross-contamination during the manufacturing process with Etodolac, a non-steroidal anti-inflammatory drug. The population at risk includes those who are hypersensitive to Etodolac, acetylsalicylic acid (ASA) or any other non-steroidal anti-inflammatory drug (NSAID). The risks include mild skin rashes, hives, and in rare instances, anaphylactoid reactions have also been reported during drug therapy with Etodolac. For most adult patients, exposure to trace amounts of Etodolac will not represent a health risk and there are no contraindications for taking the two medications together.

Dosage

Do not discontinue treatment with RAN-Gabapentin from the affected batch unless you have a history of anaphylaxis with NSAIDs. If you have a history of anaphylaxis with NSAIDs, speak to your pharmacist or doctor as soon as possible about obtaining unaffected medication or an alternative treatment. If you are on affected product and are having symptoms of allergic reaction, seek immediate attention. Contact your health care professional to obtain medical advice if you have taken any of the affected product and have concerns about your health. Report any adverse events to Health Canada .